Adherence to recommendations for the use of anti–tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adherence to recommendations for the use of anti–tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis
Authors
Keywords
-
Journal
RHEUMATOLOGY
Volume 57, Issue 5, Pages 880-890
Publisher
Oxford University Press (OUP)
Online
2018-01-20
DOI
10.1093/rheumatology/kex514
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort
- (2016) Anna Molto et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort
- (2015) Maxime Dougados et al. JOINT BONE SPINE
- Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
- (2015) J. Sieper et al. Arthritis & Rheumatology
- Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Maxime Dougados et al. Arthritis & Rheumatology
- Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
- (2013) R Landewé et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort
- (2012) Cécile Escalas et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
- (2012) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
- (2011) D. van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Spondyloarthritis
- (2011) Maxime Dougados et al. LANCET
- The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
- (2010) M. Rudwaleit et al. ANNALS OF THE RHEUMATIC DISEASES
- The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
- (2009) M Rudwaleit et al. ANNALS OF THE RHEUMATIC DISEASES
- Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis
- (2009) M. RUDWALEIT et al. JOURNAL OF RHEUMATOLOGY
- Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
- (2008) C Lukas et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two
- (2008) Hildrun Haibel et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
- (2008) Robert D. Inman et al. ARTHRITIS AND RHEUMATISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started